Clinical Trial Update: Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke [Phase 2, Phase 3]

View source ↗

Summary

A multicenter efficacy study of recombinant human erythropoietin in acute ischemic stroke, including middle cerebral artery infarction, completed Phase 2 and Ph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Middle Cerebral Artery Infarction
• Stroke

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: Max-Planck-Institute of Experimental Medicine | Conditions: Infarction, Middle Cerebral Artery, Middle Cerebral Artery Stroke | Phase 2, Phase 3 | Status: COMPLETED